Exemplos de uso de Both regimens em Inglês e suas traduções para o Português
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Official/political
Both regimens were administered every 3 weeks.
Efficacy and safety were similar for both regimens.
Both regimens were well- tolerated by these patients.
Mortality in the presence of hepatic injury occurred in less than 1% of patients in both regimens.
Both regimens were administered on day 1 every 3 weeks.
CPK elevations and rhabdomyolysis:CPK elevations of any grade were observed in 23-26% of patients in both regimens.
Both regimens were administered once every 3 weeks for 6 cycles.
In cirrhotic patients relapses occurred with both regimens, and in the absence and presence of baseline NS5A RAVs.
Both regimens were administered once every 3 weeks for 6 cycles.
Similar clinical success(point estimate for treatment difference -1.7, 95% CI -8.4, 4.9)was observed for both regimens.
In patients aged≥ 75 years, both regimens, BR-CAP as well as R-CHOP, were less tolerated see section 4.8.
Trough drug exposures remain at least twenty fold greater than the mean IC95 throughout the dosing interval for both regimens.
Both regimens appeared to be equally effective, although more research is needed to confirm this.
However, the resolution of endoscopic esophagitis was similar in both regimens pantoprazole 6/11, 54.5% and association 12/17, 70.5%A.
The GRAVITAS study assessed 2,214 patients with poor response to clopidogrel as determined by VerifyNow 12-24 h after elective angioplasty with pharmacological stents who were randomly assigned to receive a high dose of the drug loading dose of 600 mg and maintenance dose of 150 mg/day or standard dose, without a loading dose andwith a maintenance dose of 75 mg/day both regimens administered for 6 months.
A similar virologic response was observed for both regimens point estimate for treatment difference at week 48: 0.39%, 95% CI: -6.63, 7.40.
After 48 weeks on treatment there was no significant difference in the proportion of participants in each arm who had a viral load below 50 copies/ml(74.5% in the dolutegravir arm and69% in the efavirenz arm) but the study did find that both regimens were less effective at higher viral load levels.
In both AS studies,Cosentyx-treated patients(150 mg in AS Study 2 and both regimens in AS Study 1) demonstrated significantly improved signs and symptoms at Week 16, with comparable magnitude of response and efficacy maintained up to Week 52 in both anti-TNFα-naive and anti-TNFα-IR patients.
The most common serious adverse reactions(≥ 2%) reported with belatacept in both regimens(more intensive[MI] and less intensive[LI]) cumulative up to Year 3 were urinary tract infection, CMV infection, pyrexia, increased blood creatinine, pyelonephritis, diarrhoea, gastroenteritis, graft dysfunction, leukopenia, pneumonia, basal cell carcinoma, anaemia, dehydration.
Response was similar in both dosing regimens and across patient age.
Also, both dosing regimens were effective in reducing the viral load.
After CPB, the hemodynamic profile andvasoactive support were similar in both anesthetic regimens.
Both Cimzia regimens showed sustained clinical response and were statistically significant compared to placebo at week 34.
Both anesthetic regimens promoted effective anesthesia and they could be easily complemented with isoflurane to control hyperdynamic responses.
Both dose regimens were effective and not statistically different from thyroid hormone withdrawal in stimulating radioiodine uptake for diagnostic imaging.
With both TE regimens, more than 70% of patients maintained their BCVA with an average visit frequency of≥2 months.
Adverse events in both treatment regimens did not differ, the main such events being infection, gastrointestinal disorders, and infusion reactionsA.
Stem-cell reinfusion was performed on day 0 and G-CSF 300 mg SC, twice a day,was started from day 1 until engraftment in both conditioning regimens.
There was a 35% increase in serious adverse events NNH:3 with both certolizumab regimens. There were no differences in response or adverse events between the certolizumab dosesA.
Both dose regimens improved the sensitivity, accuracy and negative predictive value of Thyrogen-stimulated thyroglobulin alone or in combination with radioiodine imaging as compared to testing performed while patients remained on thyroid hormones.